# Outset Medical, Inc.: overview OM · Nasdaq · CIK 1484612 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/om.md) · [Financials](/companies/om/financials.md) · [Filings](/companies/om/filings.md) · [Insiders](/companies/om/insiders.md) Latest reported revenue: [$31.6m](/filings/0001193125-26-338432.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-338432). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [28.7](/filings/0001193125-25-274504.md) | [29.5 d](/filings/0001193125-26-051278.md) | [29.8](/filings/0001193125-26-212481.md) | [31.4](/filings/0001193125-26-338432.md) | [29.4](/filings/0001193125-25-274504.md) | [28.9 d](/filings/0001193125-26-051278.md) | [27.9](/filings/0001193125-26-212481.md) | [31.6](/filings/0001193125-26-338432.md) | | Gross margin | % | [34.3%](/filings/0001193125-25-274504.md) | [36.5% d](/filings/0001193125-26-051278.md) | [37.2%](/filings/0001193125-26-212481.md) | [37.8%](/filings/0001193125-26-338432.md) | [39.4%](/filings/0001193125-25-274504.md) | [42.4% d](/filings/0001193125-26-051278.md) | [43.4%](/filings/0001193125-26-212481.md) | [42.0%](/filings/0001193125-26-338432.md) | | Operating margin | % | [(83.2%)](/filings/0001193125-25-274504.md) | [(74.2%) d](/filings/0001193125-26-051278.md) | [(55.1%)](/filings/0001193125-26-212481.md) | [(53.7%)](/filings/0001193125-26-338432.md) | [(53.7%)](/filings/0001193125-25-274504.md) | [(61.1%) d](/filings/0001193125-26-051278.md) | [(60.7%)](/filings/0001193125-26-212481.md) | [(49.6%)](/filings/0001193125-26-338432.md) | | Net margin | % | [(97.5%)](/filings/0001193125-25-274504.md) | [(87.0%) d](/filings/0001193125-26-051278.md) | [(86.7%)](/filings/0001193125-26-338432.md) | [(59.0%)](/filings/0001193125-26-338432.md) | [(60.6%)](/filings/0001193125-25-274504.md) | [(67.5%) d](/filings/0001193125-26-051278.md) | [(68.1%)](/filings/0001193125-26-338432.md) | [(56.8%)](/filings/0001193125-26-338432.md) | | Diluted EPS | $ per share | [(8.02)](/filings/0001193125-25-274504.md) | not reported | [(3.66)](/filings/0001193125-26-212481.md) | [(1.04)](/filings/0001193125-26-338432.md) | [(1.00)](/filings/0001193125-25-274504.md) | not reported | [(1.03)](/filings/0001193125-26-212481.md) | [(0.97)](/filings/0001193125-26-338432.md) | | Free cash flow | $m | [(21.0) d](/filings/0001193125-25-274504.md) | [(16.5) d](/filings/0001193125-26-051278.md) | [(25.8)](/filings/0001193125-26-212481.md) | [(5.1) d](/filings/0001193125-26-338432.md) | [(6.5) d](/filings/0001193125-25-274504.md) | [(9.7) d](/filings/0001193125-26-051278.md) | [(12.9)](/filings/0001193125-26-212481.md) | [(9.7) d](/filings/0001193125-26-338432.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [103](/filings/0000950170-24-018093.md) | [115](/filings/0000950170-25-030045.md) | [130](/filings/0001193125-26-051278.md) | [114](/filings/0001193125-26-051278.md) | [119](/filings/0001193125-26-051278.md) | | Gross margin | % | [7.4%](/filings/0000950170-24-018093.md) | [15.5%](/filings/0000950170-25-030045.md) | [22.2%](/filings/0001193125-26-051278.md) | [33.9%](/filings/0001193125-26-051278.md) | [39.1%](/filings/0001193125-26-051278.md) | | Operating margin | % | [(127.2%)](/filings/0000950170-24-018093.md) | [(139.6%)](/filings/0000950170-25-030045.md) | [(130.2%)](/filings/0001193125-26-051278.md) | [(99.7%)](/filings/0001193125-26-051278.md) | [(55.8%)](/filings/0001193125-26-051278.md) | | Net margin | % | [(128.6%)](/filings/0000950170-24-018093.md) | [(141.2%)](/filings/0000950170-25-030045.md) | [(132.5%)](/filings/0001193125-26-051278.md) | [(112.6%)](/filings/0001193125-26-051278.md) | [(68.3%)](/filings/0001193125-26-051278.md) | | Diluted EPS | $ per share | [(2.89)](/filings/0000950170-24-018093.md) | [(3.38)](/filings/0000950170-25-030045.md) | [(52.28)](/filings/0001193125-26-051278.md) | [(36.96)](/filings/0001193125-26-051278.md) | [(5.37)](/filings/0001193125-26-051278.md) | | Free cash flow | $m | [(133)](/filings/0000950170-24-018093.md) | [(154)](/filings/0000950170-25-030045.md) | [(135)](/filings/0001193125-26-051278.md) | [(117)](/filings/0001193125-26-051278.md) | [(47.1)](/filings/0001193125-26-051278.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/om/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $11.8m | 2,742,887 | | Added +1,214 | | [BML Capital Management, LLC](/funds/1616824.md) | 2026-06-30 | $10.9m | 2,519,701 | | Added +617,500 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $4.3m | 998,961 | | Added +190,676 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $3.6m | 833,333 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.4m | 780,134 | | Added +16,312 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $2.9m | 665,847 | | Reduced −283,550 | | [PFM Health Sciences, LP](/funds/1442756.md) | 2026-06-30 | $2.5m | 582,122 | | Reduced −12,508 | | [Ensign Peak Advisors, Inc](/funds/1454984.md) | 2026-06-30 | $1.9m | 434,341 | | Reduced −92,244 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.8m | 418,211 | | Reduced −845,008 | | [Assenagon Asset Management S.A.](/funds/1546007.md) | 2026-06-30 | $1.5m | 339,438 | | Reduced −164,655 | ## Recent filings [All 725 filings](/companies/om/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-28 | 20:05 ET | [8-K](/filings/0001193125-26-374323.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-374323 | | 2026-08-06 | 21:15 ET | [10-Q](/filings/0001193125-26-338432.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338432 | | 2026-08-06 | 20:05 ET | [8-K](/filings/0001193125-26-337953.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337953 | | 2026-06-17 | 20:05 ET | [8-K](/filings/0001193125-26-274135.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-274135 | | 2026-06-05 | 20:05 ET | [8-K](/filings/0001193125-26-259527.md) | 5.07 Shareholder vote results | 0001193125-26-259527 | | 2026-05-29 | 20:05 ET | [8-K](/filings/0001193125-26-248237.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-248237 | | 2026-05-07 | 21:30 ET | [10-Q](/filings/0001193125-26-212481.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212481 | | 2026-05-07 | 20:16 ET | [8-K](/filings/0001193125-26-211980.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211980 | | 2026-04-24 | 20:06 ET | [DEF 14A](/filings/0001193125-26-177150.md) | Proxy statement, period 2026-06-04 | 0001193125-26-177150 | | 2026-02-13 | 21:01 ET | [10-K](/filings/0001193125-26-051278.md) | Annual report, period 2025-12-31 | 0001193125-26-051278 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-051278.md), filed Feb 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/03d9d692-f9ce-48c0-bd9a-d3ab1f01b31b) ## About the filer - CIK: 1484612 - Tickers: OM - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.